PharmaShots | Incisive News in 3 Shots

Subscribe Now

Hypereosinophilic Syndrome

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as the First Treatment for Hypereosinophilic Syndrome

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as the First Treatment for Hypereosinophilic Syndrome

September 28, 2020

GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome

GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome

November 13, 2019

AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

February 7, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us